Leukemia Drug Company Spikes

Good morning Wake-Up Watchlisters! While you’re sipping coffee you’ll see stock futures slumped on Friday. Investors are awaiting the latest monthly jobs report, with early surveys from Bloomberg expecting payrolls grew by 200,000 for the month. Oil is also on pace for its biggest weekly gain in nearly two months.

With oil seeing major price shifts in light of the Ukraine/Russia conflict and other global factors in 2022, we think it’s important for you to know this. Right now there’s an energy stock that could be looking at sales growth of 2,400%! All thanks to a major blunder by Russia President Vladimir Putin.

Click here to discover this stock.

Here’s a look at the top-moving stocks this morning.

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL)

Rigel Pharmaceuticals is up 41.07% premarket after the company’s received FDA Approval for REZLIDHIA, a drug for the treatment of adult patients with relapsed or refractory acute myeloid leukemia. It’s purpose is to reduce 2-hydroxyglutarate levels and regulate normal cellular differentiation of myeloid cells.

The medical industry has a history of innovation – this innovation leads to major stock gains for the right companies. Right now our friend Alexander Green is pounding the table on a medical device company he believes is ‘the biggest healthcare innovation in half a century.’

Click here to unlock this $3 stock.

Asana, Inc. (NYSE: ASAN)

Asana is down 17.37% premarket after reporting adjusted net losses of $0.26 per share. Cash outflow was also worse than the same period a year earlier. However, revenue was up 41% year over year to $141 million, boasting 78% more customers who spend at least $100,000 per year on the software.

ZScaler, Inc. (Nasdaq: ZS)

ZScaler is down 9.46% premarket after the cybersecurity company said longer sales cycles are leading to conservative guidance. Deals are taking about 4 months longer to close, according to the company. Despite the service issue, growth is still strong, with revenue up 54% year over year. Zscaler’s calculated billings climbed 37% compared to the same period last year, and deferred revenue topped the $1 billion mark.

Tech companies have seen major headwinds in 2022, and 2023 is shaping up to be a potential game-changing year for the sector. Our friend Andy Snyder has seen this pattern before, and he believes a new group of tech stocks are about to takeover. If you get in on the RIGHT STOCK at this time, you could make life-changing profits.

See which stock Andy Snyder is looking at for the predicted $13 trillion tech revolution.

Marvell Technology Inc. (Nasdaq: MRVL)

Marvell is down 5.07% premarket after inventory reductions at its storage customers impacted near-term results and guidance. Marvel said current quarter revenues would likely hit $1.4 billion, representing a year-on-year decline around 9%. For the three months endings in October, Marvel posted adjusted earnings of 57 cents per share missing forecasts by 2 cents.

Those are the top market movers today.

Happy trading!

The Wake-Up Watchlist Research Team

Popular posts